Figure 2From: Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay Median inhibition by zoledronic acid and fluvastatin alone and in combination in a) breast carcinomas tested with fluvastatin concentration A (n = 9); b) ovarian carcinomas tested with fluvastatin concentration A (n = 8) and c) ovarian carcinomas tested with fluvastatin concentration B (n = 14). The combination results are expressed as micromolar concentrations of zoledronic acid.Back to article page